CHINA - Teams with Israel for Solid Tumor Cure

Arno Froese

Israel’s Enlivex Therapeutics announced a clinical collaboration with China’s BeiGene to evaluate the safety and efficacy of combining macrophage reprogramming and an anti-PD-1 immune checkpoint inhibitor to improve the treatment of patients with advanced-stage solid tumors.

BeiGene is considered one of the leading companies in the world in the area of cancer immunotherapies, trades on NASDAQ, and has a current market capitalization of $25 billion. The company developed Tislelizumab, an anti-PD-1 immune checkpoint inhibitor. The drug is approved for various cancer indications in China, and Novartis, a large pharmaceutical company, partnered with BeiGene to market the product in the United States and Europe. According to the BeiGene investor presentation, Novartis/BeiGene expect to receive marketing approval in Europe this year and submit a request for approval from the US Food & Drug Administration, for various indications.

BeiGene was founded in 2010 and reported $1.3 billion in annual product revenue last year. The company employs more than 9,000 people on five continents and has more than 20,000 people enrolled in 110 clinical trials. The average analyst consensus 12-month price for BeiGene is $303.

If the trial is successful, it will ratify the promising results of multiple pre-clinical studies of Allocetra in combination with other cancer-fighting treatments that were released last year. In one, conducted in collaboration with Yale Cancer Center, mice with ovarian cancer that received a combination therapy of Allocetra and anti-PD1 immune checkpoint inhibitors showed an 83% increase in survival duration., 12 April 2023

Arno's Commentary

Israel teaming together with the world’s largest nation by population, communist China, is of major significance. Their population of over 1.4 billion represents more than four times the population of the US, the third largest country in the world. Thus, the marketing possibilities are virtually unlimited.

When it comes to intelligence, a paper in the National Library of Medicine ( has this to say: “The debate about ‘race’ and ‘intelligence’ seems to be never ending. The ‘special nature’ of the intelligence ascribed to ‘Jews’ has recently reappeared in an essay by one of the authors of the notorious study of race and intelligence—The Bell Curve. How this debate is constructed and what its implications are for the reappearance of ‘race’ as a category in medical and biological science is at the core of this present essay.” According to Wikipedia, when it comes to Nobel Prizes, of the over 900 individuals who’ve been recognized, 20% were Jewish.

What this article and many others repeatedly confirm is the special position of the Jews. It was Jesus Himself who stated that salvation is of the Jews. It’s from this people we have our Bible. Way back in olden times some 3,500 years ago, it was the Gentile prophet Balaam who saw the coming of the Messiah and identified this special people in Numbers 23:9: “For from the top of the rocks I see him, and from the hills I behold him: lo, the people shall dwell alone, and shall not be reckoned among the nations.”

Arno Froese is the executive director of Midnight Call Ministries and editor-in-chief of the acclaimed prophetic magazines Midnight Call and News From Israel. He has authored a number of well-received books, and has sponsored many prophecy conferences in the U.S., Canada, and Israel. His extensive travels have contributed to his keen insight into Bible prophecy, as he sees it from an international perspective.

Read more from this author

ContactAbout UsPrivacy and Safety